Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global multiple sclerosis therapies market experienced moderate growth during 2014-2019. Looking forward, the global multiple sclerosis therapies market to continue its moderate growth during the next five years.
Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy.
The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.
The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS.
Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market.
Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Questions Answered in This Report:
- How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
- What are the key regional markets?
- What is the breakup of the market based on the drug?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global multiple sclerosis therapies market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Multiple Sclerosis Therapies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug
6.1 Immunomodulators
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Copaxone
6.1.2.2 Avonex/Plegridy
6.1.2.3 Gilneya
6.1.2.4 Tysabri
6.1.2.5 Betaseron/Extavia
6.1.2.6 Tecifidera
6.1.2.7 Rebif
6.1.2.8 Ampyra
6.1.3 Market Forecast
6.2 Immunosuppressants
6.2.1 Market Trends
6.2.2 Major Types
6.1.2.1 Aubagio
6.1.2.2 Lemtrada
6.1.2.3 Ocrelizumab
6.1.2.4 Zinbryta
6.2.3 Market Forecast
7 Market Breakup by Drug Type
7.1 Biologic Drugs
7.2 Small Molecule Drugs
8 Market Breakup by Route of Administration
8.1 Oral
8.2 Injectable
8.3 Intravenous
9 Market Breakup by Distribution Channel
9.1 Hospitals Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
10 Market Breakup by Region
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- Abbvie Inc.
- Bayer Aktiengesellschaft
- Biogen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/xycnp5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.